2 names are moving together; 100% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| HUMA | Humacyte, Inc. | Healthcare | +3.0% | Most structurally connected |
| SPCE | Virgin Galactic Holdings, Inc. | Industrials | +8.3% | Group member |
Cohort
2 namesParticipation
100% this sessionObserved history
1 daily buildsFiling coverage
2/2 memberscapital investment / capacity affecting capex
“Humacyte estimates that it will incur savings due to the workforce and other operating cost reductions, and reduced capital expenditures, net of termination severance and benefits, totaling approximately $13.8 million in 2025 and up to approximately $38.0 million in 2026.”
HUMA 10-Q
product pipeline / R&D affecting expense
“The increase in selling, general and administrative expenses compared to the prior period of $0.3 million, or 4% , was primarily driven by the commercial launch of Symvess, and included a $0.8 million increase in payroll and personnel expenses and $0.3 million increase in professional fees, partially offset by a $1.0 million decrease in external services and consulting expenses.”
HUMA 10-Q
tariffs / trade costs affecting expense
“If we fail to comply with applicable anti-corruption laws and other legal requirements, we may become subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, including the loss of export or import privileges and debarment, and face substantial legal expenses.”
HUMA 10-K
Human Tissue Engineering can stay leader-led if secondary names fail to join while HUMA keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.